Table 1.

Baseline characteristics

Variables	Median [range] or n (%)
	MPN-AML (n=21)	MPN-AP (n= 13)	High risk DIPSS plus PMF (n= 11)
Age in years	64 [45–82]	63 [50–81]	67 [55–77]
Gender
Male	16 (76)	8 (62)	8 (73)
Female	5 (24)	5 (38)	3 (27)
Initial MPN
ET	4 (19)	2 (15)	0 (0)
PV	5 (24)	5 (39)	0 (0)
PMF	10 (48)	6 (46)	11 (100)
MPNu	2 (10)	0 (0)	0 (0)
WBC (109/L)	8 [1–55]	11.6 [1–50]	41.5 [2–140]
Hb (g/dl)	9 [8.3–11.5]	9.5 [6–11.7]	9.2 [7.7–11.7]
Plt (109/L)	39 [3–1912]	73 [14–267]	69 [9–860]
Bone marrow blasts (%)	31 [21–81]	14 [10–17]	2 [0–9]
JAK2V617F mutation	11 (52)	8 (62)	7 (64)
FLT3 ITDa	1 (5)	1 (8)	0
RASb	0	0	2 (25)
IDH1/2c	0	2 (28)	0
DNMT3Ad	0	0	0
ASXL1e	0	0	0
NPM-1f	0	1 (14)	0
EZH2g	0	0	0
TET2h	0	0	0
SRSF2i	0	0	0
Cytogenetics[1, 3]
Unfavorable*	12 (57)	6 (46)	2 (18)
No. of prior therapies for MPN	1 [0–4]	2 [1–5]	1 [0–4]
Time to Decitabine (months)	8 [0.5–241]	65 [0–389]	19 [3–195]
Decitabine as a:
1st line of therapy	12 (57)	1 (8)	2 (18)
2nd line of therapy	8 (38)	2 (15)	4 (36)
3rd or greater line of therapy	1 (5)	10 (77)	5 (45)
Decitabine alone	12 (57)	12 (92)	5 (45)
Decitabine + gemtuzumab ozogamicin	7 (33)	0 (0)	5 (45)
Decitabine + ruxolitinib	2 (10)	1 (8)	1 (10)
No. decitabine cycles	2 [1–15]	2 [1–37]	3 [1–8]
Mortality after ≤ 4 weeks of therapy	0 (0)	0 (0)	0 (0)

DIPSS; dynamic international prognostic scoring system, MPN; myeloproliferative neoplasm, ET; essential thrombocytosis, PV; polycythemia vera, PMF; primary myelofibrosis, AML; acute myeloid leukemia, AP; accelerated phase, WBC; white blood cell, Hb; hemoglobin, Plt; platelet.

^*Unfavorable: (complex, +8, -7/7q-, i (17q), -5/5q-, 12p-, inv (3), or 11q23).

^a18 MPN-AML, 12 MPN-AP and 8 PMF patients were evaluated for FLT3 ITD;

^b12 MPN-AML, 8 MPN-AP and 8 PMF were evaluated for RAS;

^c12 MPN-AML, 7 MPN-AP and 6 PMF evaluated for IDH1/2;

^d,e,g,h,i5 MPN-AML, 5 MPN-AP and 6 PMF were evaluated for ASXL1, DNMT3A, EZH2, TET2 and SRSF2;

^f10 MPN-AML, 7 MPN-AP and 7 PMF patients were evaluated for NPM-1 mutation.